|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells显示文摘 | Eiji Kobayashi Hiroyuki Kishi Tatsuhiko Ozawa Hiroshi Hamana Hidetoshi Nakagawa Aishun Jin Zhezhu Lin Atsushi Muraguchi | 2014 | Biochemical and Biophysical Research Communications2014，，： | 2 |
| 2 | MiRNAs and lncRNAs in NK cell biology and NK/T-cell lymphoma显示文摘The important role of lncRNAs and miRNAs in directing immune responses has become increasingly clear.Recent evidence conforms that miRNAs and lncRNAs are involved in NK cell biology and diseases through RNAeprotein,RNAeRNA,or RNAeDNA interactions.In this view,we summarize the contribution of miRNAs and lncRNAs to NK cell lineage devel-opment,activation and function,highlight the biological significance of functional miRNAs or lncRNAs in NKTL and discuss the potential of these miRNAs and lncRNAs as innovative bio-markers/targets for NKTL early diagnosis,target treatment and prognostic evaluations. | Fengxia Gao Sirong He Aishun Jin | 2021 | Genes & Diseases2021，8，5： | 1 |
| 3 | BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells显示文摘 | Daisuke Mizuchi Tetsuya Kurosu Aiko Kida Zhen-Hua Jin Aishun Jin Ayako Arai Osamu Miura | 2004 | Biochemical and Biophysical Research Communications2004，，3： | 1 |
| 4 | A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is still rapidly spreading worldwide.Many drugs and vaccines have been approved for clinical use show efficacy in the treatment and prevention of SARS-CoV-2 infections.However,the emergence of SARS-CoV-2 variants of concern(VOCs),such as Delta(B.1.617.2)and the recently emerged Omicron(B.1.1.529),has seriously challenged the application of current therapeutics.Therefore,there is still a pressing need for identification of new broad-spectrum antivirals.Here,we further characterized a human antibody(58G6),which we previously isolated from a patient,with a broadly authentic virus-neutralizing activity that inhibits the Delta and Omicron variants with half-maximal inhibitory concentrations(ICso)of 1.69 ng/ml and 54.31 ng/ml,respectively.58G6 shows prophylactic and therapeutic effcacy in hamsters challenged with the Delta and Omicron variants through nasal delivery.Notably,a very low dosage(2 mg/kg daily)of 58G6 efficiently prevented Omicron variant replication in the lungs.These advantages may overcome the efficacy limitation of currently approved neutralizing antibodies that can be administered only by intravenous injection.In general,58G6 is a promising prophylactic and therapeutic candidate against current circulating VOCs and even future emerging mutants.To the best of our knowledge,58G6 is one of the most potent neutralizing antibodies against Omicron,with a broader spectrum than those approved for clinical use.58G6 could be developed as a nebulized therapy,which would be more cost effective and user friendly and enhance the clinical outcome comparedto thatobtainedwithdirect nasaldelivery. | Xinghai Zhang Huajun Zhang Tingting Li Shaohong Chen Feiyang Luo Junhui Zhou Peiyi Zheng Shuyi Song Yan Wu Tengchuan Jin Ni Tang Aishun Jin Chengyong Yang Guofeng Cheng Rui Gong Sandra Chiu Ailong Huang | 2022 | Signal Transduction and Targeted Therapy2022，7，9： | 1 |
| 5 | Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19显示文摘Previously,we identified an antibody combination A8G6 that showed promising efficacy in COVID-19 animal models and favorable safety profile in preclinical models as well as in a first-in-human trial.To evaluate the real-word efficacy of A8G6 neutralizing antibody nasal spray in post-exposure prophylaxis of COVID-19,an open-label,non-randomized,two-arm,blank-controlled,investigator-initiated trial was conducted in Chongqing,China(the register number:ChiCTR2200066416).High-risk healthy participants(18–65 years)within 72 h after close contact to COVID-19 patients were recruited and received a three-dose(1.4 mg/dose)A8G6 treatment daily or no treatment(blank control)for 7 consecutive days.SARS-CoV-2 infection occurred in 151/340(44.4%)subjects in the blank control group and 12/173(6.9%)subjects in the A8G6 treatment group.The prevention efficacy of the A8G6 treatment within 72 h exposure was calculated to be 84.4%(95%CI:74.4–90.4%).Moreover,compared to the blank-control group,the time from the SARS-CoV-2 negative to the positive COVID-19 conversion was significantly longer in the AG86 treatment group(mean time:3.4 days vs 2.6 days,p=0.019).In the secondary end-point analysis,the A8G6 nasal treatment had no effects on the viral load at baseline SARS-CoV-2 RT-PCR positivity and the time of the negative COVID-19 conversion.Finally,except for 5 participants(3.1%)with general adverse effects,we did not observe any severe adverse effects related to the A8G6 treatment.In this study,the intranasal spray AG86 antibody cocktail showed potent efficacy for prevention of SARS-CoV-2 infection in close contacts of COVID-19 patients. | Xiaosong Li Pai Peng Haijun Deng Qian Yang Shi Chen Benhua Li Miao He Aishun Jin Zhu Yang Ni Tang Ailong Huang | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
| 6 | Identification of cross-reactive CD8^(+)T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants显示文摘Despite the growing knowledge of T cell responses in COVID-19 patients,there is a lack of detailed characterizations for T cell-antigen interactions and T cell functions.Here,with a predicted peptide library from SARS-CoV-2 S and N proteins,we found that specific CD8+T cell responses were identified in over 75%of COVID-19 convalescent patients(15/20)and an epitope from the N protein,N361-369(KTFPPTEPK),was the most dominant epitope from our selected peptide library.Importantly,we discovered 2 N361-369-specific T cell receptors(TCRs)with high functional avidity that were independent of the CD8 co-receptor.These TCRs exhibited complementary cross-reactivity to several presently reported N361-369 mutant variants,as to the wild-type epitope.Further,the natural functions of these TCRs in the cytotoxic immunity against SARS-CoV-2 were determined with dendritic cells(DCs)and the lung organoid model.We found that the N361-369 epitope could be normally processed and endogenously presented by these different types of antigen presenting cells,to elicit successful activation and effective cytotoxicity of CD8+T cells ex vivo.Our study evidenced potential mechanisms of cellular immunity to SARS-CoV-2,and illuminated potential ways of viral clearance in COVID-19 patients.These results indicate that utilizing CD8-independent TCRs against SARS-CoV-2-associated antigens may provide functional superiority that is beneficial for the adoptive cell immunotherapies based on natural or genetically engineered T cells.Additionally,this information is highly relevant for the development of the next-generation vaccines with protections against continuously emerged SARS-CoV-2 mutant strains. | Chao Hu Meiying Shen Xiaojian Han Qian Chen Luo Li Siyin Chen Jing Zhang Fengxia Gao Wang Wang Yingming Wang Tingting Li Shenglong Li Jingjing Huang Jianwei Wang Ju Zhu Dan Chen Qingchen Wu Kun Tao Da Pang Aishun Jin | 2022 | Genes & Diseases2022，9，1： | 0 |
| 7 | Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies显示文摘The pandemic of COVID-19 caused by SARS-CoV-2 has made serious threats to the public health.Antibodies have been considered as promising therapeutics for the prevention and treatment of pathogens.So far,effectors that can influence the sustainability of SARS-CoV-2 specific antibodies in COVID-19 patients are still unclear.In this paper,we attempted to find potential key factors correlated with SARS-CoV-2 specific antibodies.Transcriptional analysis with the peripheral blood mononuclear cells(PBMCs)revealed proportional changes of immune cell subsets in COVID-19 convalescent patients,including a substantial decrease of monocytes and evident increase of dendritic cells(DCs).Moreover,we found that the gene expressions of chemokines associated with monocyte/macrophage were significantly up-regulated during the COVID-19 recovery phase.Most importantly,we found a set of 27 immune genes corresponding to a comparatively lower amount of SARS-CoV-2 specific antibodies,and identified two hub genes,IL1βand IL6,the protein expressions of which exhibited negative correlation with the immunoglobulin G(IgG)levels in COVID-19 convalescent sera.In addition,we found that high expressions of these 2 hub genes during the convalescent stage were negatively associated with the plasma cell marker CD138.Our study presented two key inflammatory factors correlated to the low level of SARS-CoV-2 specific antibodies,which indicated the potential regulatory process of plasmatic antibodies levels in some COVID-19 convalescent patients. | Shenglong Li Wang Wang Tingting Li Xiaojian Han Chao Hu Yingming Wang Meiying Shen Li Du Yaru Nai Jianwei Wang Aishun Jin | 2022 | Genes & Diseases2022，9，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员